122 related articles for article (PubMed ID: 38122924)
1. High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.
Monzo L; Girerd N; Ferreira JP; Lamiral Z; Anker SD; Cleland JGF; Kondo T; McMurray JJV; Lam CSP; Mehra MR; Veldhuisen DJV; Greenberg B; Zannad F
J Card Fail; 2024 Apr; 30(4):618-623. PubMed ID: 38122924
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
[TBL] [Abstract][Full Text] [Related]
3. Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial.
Ferreira JP; Lam CSP; Anker SD; Mehra MR; van Veldhuisen DJ; Byra WM; La Police DA; Cleland JGF; Greenberg B; Zannad F
Eur J Heart Fail; 2021 Apr; 23(4):648-656. PubMed ID: 32959502
[TBL] [Abstract][Full Text] [Related]
4. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
[TBL] [Abstract][Full Text] [Related]
5. Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.
Cunningham JW; Ferreira JP; Deng H; Anker SD; Byra WM; Cleland JGF; Gheorghiade M; Lam CSP; La Police D; Mehra MR; Neaton JD; Spiro TE; van Veldhuisen DJ; Greenberg B; Zannad F
JACC Heart Fail; 2020 May; 8(5):359-368. PubMed ID: 32171760
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
Zannad F; Greenberg B; Cleland JG; Gheorghiade M; van Veldhuisen DJ; Mehra MR; Anker SD; Byra WM; Fu M; Mills RM
Eur J Heart Fail; 2015 Jul; 17(7):735-42. PubMed ID: 25919061
[TBL] [Abstract][Full Text] [Related]
7. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Zannad F; Anker SD; Byra WM; Cleland JGF; Fu M; Gheorghiade M; Lam CSP; Mehra MR; Neaton JD; Nessel CC; Spiro TE; van Veldhuisen DJ; Greenberg B;
N Engl J Med; 2018 Oct; 379(14):1332-1342. PubMed ID: 30146935
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.
Sharma A; Caldeira D; Razaghizad A; Pinto FJ; van Veldhuisen DJ; Mehra MR; Lam CSP; Cleland J; Anker SD; Greenberg B; Ferreira JP; Zannad F
BMJ Open; 2023 Aug; 13(8):e068865. PubMed ID: 37567750
[TBL] [Abstract][Full Text] [Related]
10. Combined Assessment of D-Dimer with the Get with the Guidelines-Heart Failure Risk Score and N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Acute Decompensated Heart Failure with Preserved and Reduced Ejection Fraction.
Naruse H; Ishii J; Takahashi H; Kitagawa F; Sakaguchi E; Nishimura H; Kawai H; Muramatsu T; Harada M; Yamada A; Fujiwara W; Hayashi M; Motoyama S; Sarai M; Watanabe E; Ito H; Ozaki Y; Izawa H
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441860
[TBL] [Abstract][Full Text] [Related]
11. New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial.
Ferreira JP; Cleland JG; Lam CSP; Anker SD; Mehra MR; van Veldhuisen DJ; Byra WM; LaPolice DA; Greenberg B; Zannad F
Clin Res Cardiol; 2022 Jan; 111(1):50-59. PubMed ID: 34128083
[TBL] [Abstract][Full Text] [Related]
12. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation.
Kondo T; Jering KS; Jhund PS; Anand IS; Desai AS; Lam CSP; Maggioni AP; Martinez FA; Packer M; Petrie MC; Pfeffer MA; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Solomon SD; McMurray JJV
Circ Heart Fail; 2023 Jul; 16(7):e010377. PubMed ID: 37350280
[TBL] [Abstract][Full Text] [Related]
13. Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction.
Girerd N; Cleland J; Anker SD; Byra W; Lam CSP; Lapolice D; Mehra MR; van Veldhuisen DJ; Bresso E; Lamiral Z; Greenberg B; Zannad F
Sci Rep; 2022 May; 12(1):8574. PubMed ID: 35595781
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of D-dimer in acute myocardial infarction complicated by heart failure with preserved ejection fraction.
Zhang X; Wang S; Sun L; Fang S; Yu B
ESC Heart Fail; 2020 Dec; 7(6):4118-4125. PubMed ID: 33103360
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulants for stroke prevention in heart failure with reduced ejection fraction.
Schäfer A; Flierl U; Bauersachs J
Clin Res Cardiol; 2022 Jan; 111(1):1-13. PubMed ID: 34448932
[TBL] [Abstract][Full Text] [Related]
16. Impact of Geographic Region on the COMMANDER-HF Trial.
Ferreira JP; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; La Police DA; Anker SD; Mehra MR; Leroy C; Eschwege V; Toussaint-Hacquard M; Rossignol P; Greenberg B; Zannad F
JACC Heart Fail; 2021 Mar; 9(3):201-211. PubMed ID: 33549557
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation versus placebo for heart failure in sinus rhythm.
Shantsila E; Kozieł M; Lip GY
Cochrane Database Syst Rev; 2021 May; 5(5):CD003336. PubMed ID: 34002371
[TBL] [Abstract][Full Text] [Related]
18. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF.
Adamson C; Welsh P; Docherty KF; de Boer RA; Diez M; Drożdż J; Dukát A; Inzucchi SE; Køber L; Kosiborod MN; Ljungman CEA; Martinez FA; Ponikowski P; Sabatine MS; Morrow DA; Lindholm D; Hammarstedt A; Boulton DW; Greasley PJ; Langkilde AM; Solomon SD; Sattar N; McMurray JJV; Jhund PS
JACC Heart Fail; 2023 Mar; 11(3):291-304. PubMed ID: 36592046
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
20. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.
Butler J; Zheng Y; Khan MS; Bonderman D; Lund LH; deFilippi CR; Blaustein RO; Ezekowitz JA; Freitas C; Hernandez AF; O'Connor CM; Voors AA; Westerhout CM; Lam CSP; Armstrong PW;
JACC Heart Fail; 2023 May; 11(5):583-592. PubMed ID: 37137660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
